SBIR/STTR Research Award
OPTIMIZE FORMULATION OF VSA ADJUVANT
Award amount
$600,000Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Adjuvax LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EGVNJG3GMEL7
- Solicitation number
- PHS-2022-1
- Topic code
- 105
Research abstract
The contract supports the development of a saponin as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against SARS-CoV-2 and pneumococcal infection.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR BASE YEAR - TOPIC 130 ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES
- Development of AS01b Mimics by Replacing QS-21 with a New Saponin Adjuvant
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Multi-omic CSF Assay for the Diagnosis of Brain Cancers
- A unified eligibility application and determination system to increase Ryan White linkage to care and retention in care by reducing structural barriers and facilitating client engagement
- Novel carriers for enhanced oligonucleotide permeability through the blood-brain barrier
- PEP/PrEP via Pharmacist-Prescribing Implementation (PEPPI)
- Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
Research funding history
3 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $4,200,000. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services